Differential roles of MAP kinases in atorvastatin-induced VEGF release in cardiac myocytes

Life Sciences

Volumn 79, Issue 12, 2006, Pages 1214-1220

  Nakajima, Keiichi ^a   Suga, Hidetaka ^a   Matsuno, Hiroyuki ^a   Ishisaki, Akira ^a   Hirade, Kouseki ^a   Kozawa, Osamu ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Atorvastatin; Cardiac myocytes; p38 MAP kinase; p44 p42 MAP kinase; VEGF

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ATORVASTATIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE; VASCULOTROPIN;

ANIMAL CELL; ARTICLE; ATTENUATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; ENZYME ACTIVITY; HEART MUSCLE CELL; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; UPREGULATION;

ANIMALS; ANTICHOLESTEREMIC AGENTS; BLOTTING, WESTERN; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FLAVONOIDS; HEPTANOIC ACIDS; IMIDAZOLES; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; MYOCYTES, CARDIAC; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PYRIDINES; PYRROLES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33746416606     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2006.03.029     Document Type: Article

References (40)

1. Alessi D.R., Cuenda A., Cohen P., Dudley D.T., and Saltiel A.R. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. Journal of Biological Chemistry 270 46 (1995) 27489-27494
2. Baumgartner I., Pieczek A., Manor O., Blair R., Kearney M., Walsh K., and Isner J.M. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 97 12 (1998) 1114-1123
3. Callister T.Q., Raggi P., Cooil B., Lippolis N.J., and Russo D.J. Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. New England Journal of Medicine 339 27 (1998) 1972-1978
4. Chang L., and Karin M. Mammalian MAP kinase signalling cascades. Nature 410 6824 (2001) 37-40
5. Cuenda A., Rouse J., Doza Y.N., Meier R., Cohen P., Gallagher T.F., Young P.R., and Lee J.C. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS letters 364 2 (1995) 229-233
6. Ding X.Z., and Adrian T.E. MEK/ERK-mediated proliferation is negatively regulated by P38 map kinase in the human pancreatic cancer cell line, PANC-1. Biochemical and Biophysical Research Communications 282 2 (2001) 447-453
7. Essig M., Nguyen G., Prie D., Escoubet B., Sraer J.D., and Friedlander G. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins. Circulation Research 83 7 (1998) 683-690
8. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. Journal of Molecular Medicine 77 7 (1999) 527-543
9. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. American Journal of Physiology. Cell Physiology 280 6 (2001) C1358-C1366
10. Ferrara N., Carver-Moore K., Chen H., Dowd M., Lu L., O'Shea K.S., Powell-Braxton L., Hillan K.J., and Moore M.W. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380 6573 (1996) 439-442
11. Flamigni F., Facchini A., Stanic I., Tantini B., Bonavita F., and Stefanelli C. Control of survival of proliferating L1210 cells by soluble guanylate cyclase and p44/42 mitogen-activated protein kinase modulators. Biochemical Pharmacology 62 3 (2001) 319-328
12. Giordano F.J., Gerber H.P., Williams S.P., VanBruggen N., Bunting S., Ruiz-Lozano P., Gu Y., Nath A.K., Huang Y., Hickey R., Dalton N., Peterson K.L., Ross J., Chien K.R., and Ferrara N. A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proceedings of the National Academy of Sciences of the United States of America 98 10 (2001) 5780-5785
13. Harada M., Itoh H., Nakagawa O., Ogawa Y., Miyamoto Y., Kuwahara K., Ogawa E., Igaki T., Yamashita J., Masuda I., Yoshimasa T., Tanaka I., Saito Y., and Nakao K. Significance of ventricular myocytes and nonmyocytes interaction during cardiocyte hypertrophy: evidence for endothelin-1 as a paracrine hypertrophic factor from cardiac nonmyocytes. Circulation 96 10 (1997) 3737-3744
14. Hernandez-Perera O., Perez-Sala D., Navarro-Antolin J., Sanchez-Pascuala R., Hernandez G., Diaz C., and Lamas S. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. Journal of Clinical Investigation 101 12 (1998) 2711-2719
15. Ishii Y., Sakai S., and Honma Y. Pyridinyl imidazole inhibitor SB203580 activates p44/42 mitogen-activated protein kinase and induces the differentiation of human myeloid leukemia cells. Leukemia Research 25 9 (2001) 813-820
16. Jones S.P., Teshima Y., Akao M., and Marbán E. Simvastatin attenuates oxidant-induced mitochondrial dysfunction in cardiac myocytes. Circulation Research 93 8 (2003) 697-699
17. Kaipainen A., Korhonen J., Pajusola K., Aprelikova O., Persico M.G., Terman B.I., and Alitalo K. The related FLT4, FLT1, and KDR receptor tyrosine kinases show distinct expression patterns in human fetal endothelial cells. Journal of Experimental Medicine 178 6 (1993) 2077-2088
18. Karkkainen M.J., Mäkinen T., and Alitalo K. Lymphatic endothelium: a new frontier of metastasis research. Nature Cell Biology 4 1 (2002) E2-E5
19. Kato K., Ito H., Hasegawa K., Inaguma Y., Kozawa O., and Asano T. Modulation of the stress-induced synthesis of hsp27 and alpha B-crystallin by cyclic AMP in C6 rat glioma cells. Journal of Neurochemistry 66 3 (1996) 946-950
20. Kothe H., Dalhoff K., Rupp J., Muller A., Kreuzer J., Maass M., and Katus H.A. Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae. Circulation 101 15 (2000) 1760-1763
21. Lathi K.G., Vale P.R., Losordo D.W., Cespedes R.M., Symes J.F., Esakof D.D., Maysky M., and Isner J.M. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease: anesthetic management and results. Anesthesia and Analgesia 92 1 (2001) 19-25
22. Laufs U., La Fata V., Plutzky J., and Liao J.K. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97 12 (1998) 1129-1135
23. Laufs U., Marra D., Node K., and Liao J.K. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). Journal of Biological Chemistry 274 31 (1999) 21926-21931
24. Levy A.P., Levy N.S., Loscalzo J., Calderone A., Takahashi N., Yeo K.T., Koren G., Colucci W.S., and Goldberg M.A. Regulation of vascular endothelial growth factor in cardiac myocytes. Circulation Research 76 5 (1995) 758-766
25. Matsuno H., Takei M., Hayashi H., Nakajima K., Ishisaki A., and Kozawa O. Simvastatin enhances the regeneration of endothelial cells via VEGF secretion in injured arteries. Journal of Cardiovascular Pharmacology 43 3 (2004) 333-340
26. Minchenko A., Bauer T., Salceda S., and Caro J. Hypoxic stimulation of vascular endothelial growth factor expression in vitro and in vivo. Laboratory Investigation 71 3 (1994) 374-379
27. Neufeld G., Cohen T., Gengrinovitch S., and Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB Journal 13 1 (1999) 9-22
28. New L., Li Y., Ge B., Zhong H., Mansbridge J., Liu K., and Han J. SB203580 promotes EGF-stimulated early morphological differentiation in PC12 cell through activating ERK pathway. Journal of Cellular Biochemistry 83 4 (2001) 585-596
29. Ogata Y., Takahashi M., Takeuchi K., Ueno S., Mano H., Ookawara S., Kobayashi E., Ikeda U., and Shimada K. Fluvastatin induces apoptosis in rat neonatal cardiac myocytes: a possible mechanism of statin-attenuated cardiac hypertrophy. Journal of Cardiovascular Pharmacology 40 6 (2002) 907-915
30. Pimentel R.C., Yamada K.A., Kléber A.G., and Saffitz J.E. Autocrine regulation of myocyte Cx43 expression by VEGF. Circulation Research 90 6 (2002) 671-677
31. Plouët J., Schilling J., and Gospodarowicz D. Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT-20 cells. EMBO Journal 8 12 (1989) 3801-3806
32. Raingeaud J., Gupta S., Rogers J.S., Dickens M., Han J., Ulevitch R.J., and Davis R.J. Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. Journal of Biological Chemistry 270 13 (1995) 7420-7426
33. Schaefer E.J., McNamara J.R., Tayler T., Daly J.A., Gleason J.L., Seman L.J., Ferrari A., and Rubenstein J.J. Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects. American Journal of Cardiology 93 1 (2004) 31-39
34. Takemoto M., and Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arteriosclerosis, Thrombosis, and Vascular Biology 21 11 (2001) 1712-1719
35. Takemoto M., Node K., Nakagami H., Liao Y., Grimm M., Takemoto Y., Kitakaze M., and Liao J.K. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. Journal of Clinical Investigation 108 10 (2001) 1429-1437
36. Takenaka M., Hirade K., Tanabe K., Akamatsu S., Dohi S., Matsuno H., and Kozawa O. Simvastatin stimulates VEGF release via p44/p42 MAP kinase in vascular smooth muscle cells. Biochemical and Biophysical Research Communications 301 1 (2003) 198-203
37. Tanaka T., Kanai H., Sekiguchi K., Aihara Y., Yokoyama T., Arai M., Kanda T., Nagai R., and Kurabayashi M. Induction of VEGF gene transcription by IL-1 beta is mediated through stress-activated MAP kinases and Sp1 sites in cardiac myocytes. Journal of Molecular and Cellular Cardiology 32 11 (2000) 1955-1967
38. Widmann C., Gibson S., Jarpe M.B., and Johnson G.L. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiological Reviews 79 1 (1999) 143-180
39. Xiao Y.Q., Malcolm K., Worthen G.S., Gardai S., Schiemann W.P., Fadok V.A., Bratton D.L., and Henson P.M. Cross-talk between ERK and p38 MAPK mediates selective suppression of pro-inflammatory cytokines by transforming growth factor-beta. Journal of Biological Chemistry 277 17 (2002) 14884-14893
40. Yang Z., Kozai T., van der Loo B., Viswambharan H., Lachat M., Turina M.I., Malinski T., and Luscher T.F. HMG-CoA reductase inhibition improves endothelial cell function and inhibits smooth muscle cell proliferation in human saphenous veins. Journal of the American College of Cardiology 36 5 (2000) 1691-1697